Impact of quadrivalent HPV vaccine dose spacing on immunologic response in women living with HIV.,Vaccine

当前位置： X-MOL 学术 › Vaccine › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Impact of quadrivalent HPV vaccine dose spacing on immunologic response in women living with HIV.
Vaccine ( IF 5.5 ) Pub Date : 2020-03-05 , DOI: 10.1016/j.vaccine.2020.02.075
Elisabeth McClymont ₁ , Gina Ogilvie ₂ , Arianne Albert ₃ , Angela Johnston ₄ , Janet Raboud ₅ , Sharon Walmsley ₅ , Nancy Lipsky ₃ , Mona Loutfy ₆ , Sylvie Trottier ₇ , Fiona Smaill ₈ , Mark H Yudin ₉ , Marina B Klein ₁₀ , Marianne Harris ₁₁ , Wendy Wobeser ₁₂ , Ari Bitnun ₁₃ , Fatima Kakkar ₁₄ , Lindy Samson ₁₅ , Jason Brophy ₁₆ , Christos Karatzios ₁₇ , Deborah Money ₁ ,

Affiliation

Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada.
School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada; Women's Health Research Institute, Vancouver, BC, Canada.
Women's Health Research Institute, Vancouver, BC, Canada.
Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Toronto General Hospital Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON, Canada.
Infectious Diseases Research Centre - Université Laval, Québec City, QC, Canada.
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON, Canada; Department of Obstetrics and Gynecology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
McGill University Health Centre, Montreal, QC, Canada.
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Departments of Public Health and Biomedical & Molecular Sciences, Queen's University, Kingston, ON, Canada.
Hospital for Sick Children, Department of Paediatrics, University of Toronto, Toronto, ON, Canada.
Department of Pediatrics, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada; Centre Maternel et Infantile sur le SIDA, CHU Sainte-Justine, Montreal, QC, Canada.
Department of Paediatrics, University of Ottawa, Ottawa, ON, Canada.
Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada.
Department of Paediatrics, Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Montreal, QC, Canada; Department of Pediatrics, Montreal Children's Hospital, McGill University Health Centre, Montreal, QC, Canada.

HPV vaccination schedules have changed as evidence has supported reduced dosing and extended intervals. Women living with HIV (WLWH) represent an important population with no data on alternative dosing.

Girls and WLWH received quadrivalent HPV (qHPV) vaccine in a pan-Canadian study of immunogenicity and efficacy. Serology was performed at months 0/2/7/12/18/24. Medical and sexual history was collected throughout. Linear regression was used to determine if spacing of doses was associated with peak antibody titer.

Multivariable analyses demonstrated significant relationships between peak antibody titer and time to blood draw post last vaccine dose, naivety to the relevant HPV type, and HIV viral load for all qHPV types. There was a significant relationship between peak HPV16/18 antibody titer and age.

Taking age, time to serology, CD4 cell count, CD4 nadir, HIV viral load, and HPV naivety into account, spacing of the three qHPV vaccine doses did not significantly impact peak antibody titers.

中文翻译：